Amphastar Pharmaceuticals (NASDAQ:AMPH) Given Daily Media Impact Score of 0.20

Media headlines about Amphastar Pharmaceuticals (NASDAQ:AMPH) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the company an impact score of 43.634329645378 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Amphastar Pharmaceuticals (NASDAQ AMPH) opened at $19.46 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. The company has a market capitalization of $894.23, a price-to-earnings ratio of 129.67, a price-to-earnings-growth ratio of 1.36 and a beta of 1.69. Amphastar Pharmaceuticals has a 12-month low of $12.05 and a 12-month high of $19.95.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.05. The company had revenue of $57.90 million for the quarter, compared to the consensus estimate of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The firm’s quarterly revenue was down 9.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.14 EPS. equities research analysts predict that Amphastar Pharmaceuticals will post -0.03 earnings per share for the current fiscal year.

Several research firms have commented on AMPH. BidaskClub raised Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Needham & Company LLC upped their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, December 1st. BMO Capital Markets upped their price objective on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a research note on Friday, November 10th. Finally, Raymond James Financial lowered Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price target on the stock. in a research report on Thursday, November 9th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average price target of $19.50.

In other news, Director Stephen B. Shohet sold 7,866 shares of the firm’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $18.87, for a total value of $148,431.42. Following the completion of the transaction, the director now owns 31,982 shares in the company, valued at approximately $603,500.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO William J. Peters sold 6,226 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $19.67, for a total value of $122,465.42. The disclosure for this sale can be found here. In the last quarter, insiders have sold 72,787 shares of company stock valued at $1,359,684. Corporate insiders own 11.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/19/amphastar-pharmaceuticals-amph-earns-daily-coverage-optimism-score-of-0-20.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply